[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638843":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":37,"centralContacts":42,"locations":49,"responsibleParty":65,"collaborators":30,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":30,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":30,"studyType":80,"phases":81,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":52,"whyStopped":30,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Guangzhou Virotech Pharmaceutical Co., Ltd.","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"VRT106 Monotherapy","EXPERIMENTAL","VRT106",[13],"Drug: VRT106",{"label":15,"type":10,"description":16,"interventionNames":17},"VRT106 Combination","VRT106 in combination with camrelizumab and apatinib",[18],"Drug: VRT106 in combination with camrelizumab and apatinib",{"label":20,"type":21,"description":22,"interventionNames":23},"Standard of Care","ACTIVE_COMPARATOR","Investigator's Choice of Standard of Care",[24],"Drug: Investigator's Choice of Standard of Care",[26,31,34],{"type":27,"name":11,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","VRT106,Intravenous infusion",[9],null,{"type":27,"name":16,"description":32,"armGroupLabels":33,"otherNames":30},"VRT106: Intravenous infusion Camrelizumab: Intravenous infusion Apatinib: Oral administration",[15],{"type":27,"name":22,"description":35,"armGroupLabels":36,"otherNames":30},"At the investigator's discretion",[20],[38],{"name":39,"affiliation":40,"role":41},"Liang Peng","Third Affiliated Hospital, Sun Yat-Sen University","STUDY_CHAIR",[43,47],{"name":39,"role":44,"phone":45,"phoneExt":30,"email":46},"CONTACT","020-85252621","pliang@mail.sysu.edu.cn",{"name":48,"role":44,"phone":30,"phoneExt":30,"email":30},"Chan Xie",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":30,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"The Third Affiliated Hospital of Sun Yat-sen University","RECRUITING","Guangzhou","Guangdong","China","CN",{"type":58,"coordinates":59},"Point",[60,61],113.25,23.11667,{"lat":61,"lon":60},[64],{"name":39,"role":44,"phone":45,"phoneExt":30,"email":46},{"type":66,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100638843","phase-2-a-study-of-vrt106-combined-with-camrelizumab-and-apatinib-for-advanced-hcc-100638843",false,"NCT07589244","A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC","A Multicenter, Open-label Phase II\u002FIII Clinical Trial of VRT106 in Combination With Camrelizumab and Apatinib in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Immune Checkpoint Inhibitor Therapy","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form (ICF), understand the nature of this study, and agree to comply with and complete all required study procedures.\n* Be aged between 18 and 75 years (inclusive) on the date of signing the ICF, regardless of gender.\n* Have a histologically or cytologically confirmed diagnosis of advanced hepatocellular carcinoma (HCC), or a clinical diagnosis of advanced HCC according to the Standard for Diagnosis and Treatment of Primary Liver Cancer(2024 Edition).\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Have an anticipated life expectancy of ≥ 3 months.\n* Have no severe hematologic, hepatic, renal, coagulation, or cardiac function abnormalities.\n\nExclusion Criteria:\n\n* Prior receipt of camrelizumab, apatinib, oncolytic viruses, or other gene therapies.\n* Receipt of other unapproved investigational drugs\u002Fdevices within 4 weeks or 5 half-lives (whichever is shorter) prior to first dose administration in this study, or immunocompromised status.\n* History of splenectomy.\n* Pregnant or breastfeeding women.","ALL","18 Years","75 Years",{"count":78,"type":79},66,"ESTIMATED","INTERVENTIONAL",[82,83],"PHASE2","PHASE3","This is an open-label phase II\u002FIII clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).",[86],"HCC",[86],"2026-05-13",{"date":90,"type":91},"2026-05-15","ACTUAL",{"date":88,"type":79},{"date":94,"type":79},"2029-06-30",{"name":5,"class":6},1]